Compare Equinox Gold Corp. Common Shares (EQX) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinox Gold Corp. Common Shares vs Hinge Health Inc. Class A Common Stock — how do they compare? Equinox Gold Corp. Common Shares trades at $10.57 (market cap $12.62B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Equinox Gold Corp. Common Shares is the larger of the two by market cap, and Equinox Gold Corp. Common Shares pays a 0.48% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinox Gold Corp. Common Shares for 6 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EQX | HNGE | |
|---|---|---|
Market Cap | $12.62B | $8.48B |
Volume | 12,370,191 | 879,799 |
Sector | Basic Materials | Health |
52-Week High | $18.76 | $105.14 |
52-Week Low | $8.62 | $31.17 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.72B | $8.10B |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinox Gold (EQX) trades at $10.85, down 3.12% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $1.82B revenue and $221M net income, and projects significant growth in 2026 to $2.9B revenue. Recent news highlights the completion of the Orla Mining merger, positioning EQX as a major North American gold producer with a path to 2 million ounces of annual production.
The outlook is positive due to transformative growth from the Orla acquisition, increased production guidance, and a 50% dividend hike. Risks include execution of mine expansions and gold price volatility. With a 100% buy rating from one analyst, the stock appears undervalued relative to its growth pipeline, though recent earnings misses warrant monitoring.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equinox Gold Corp. Common Shares
Equinox Gold is a gold mining company with operations in the Americas. It produces gold and develops additional mining projects.
Read more on EQX →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
